Skip to main content
. 2013 Sep 9;31(30):3791–3799. doi: 10.1200/JCO.2012.47.4940

Table 3.

Summary of Next-Line Therapy in the Overall Population and by Region

Category Overall Population
Central/Eastern Europe
North America/Western Europe
Rest of World
Tivozanib (n = 260)
Sorafenib (n = 257)
Tivozanib (n = 229)
Sorafenib (n = 228)
Tivozanib (n = 22)
Sorafenib (n = 18)
Tivozanib (n = 9)
Sorafenib (n = 11)
No. % No. % No. % No. % No. % No. % No. % No. %
Patients who discontinued assigned therapy* 190 73 226 88 165 72 198 87 16 73 17 94 9 100 11 100
Patients with next-line therapy 68 26 168 65 52 23 145 64 13 59 14 78 3 33 9 82
Patients with next-line targeted therapy 34 13 162 63 26 11 139 61 7 32 14 78 1 11 9 82
    VEGFR inhibitor 18 7 158 61 13 6 138 61 5 23 11 61 0 9 82
    Tivozanib 0 156 61 0 138 61 0 10 56 0 8 73
    mTOR inhibitor 16 6 4 2 13 6 1 < 1 2 9 3 17 1 11 0
    Cytokines 14 5 3 1 14 6 3 1 0 0 0 0
    Radiotherapy 10 4 2 1 4 2 2 1 5 23 0 1 11 0
    Other 10 4 1 < 1 8 3 1 < 1 1 5 0 1 11 0

Abbreviations: mTOR, mammalian target of rapamycin; VEGFR, vascular endothelial growth factor receptor.

*

On or before August 27, 2012.

One patient erroneously appears as “discontinued” but was ongoing as of August 27, 2012.